-
公开(公告)号:JP2012255004A
公开(公告)日:2012-12-27
申请号:JP2012173398
申请日:2012-08-03
Applicant: Takeda California Inc , タケダ カリフォルニア インコーポレイテッド
Inventor: AERTGEERTS KATHLEEN , BRENNAN NANCY K , CAO SHELDON X , CHANG EDCON , KIRYANOV ANDRE A , LIU YAN
IPC: C07D207/14 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/407 , A61K31/4355 , A61K31/44 , A61K31/445 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/472 , A61K31/495 , A61K31/496 , A61K31/498 , A61K31/4985 , A61K31/506 , A61K31/5377 , A61K31/538 , A61P3/00 , A61P3/10 , A61P9/12 , A61P19/10 , A61P25/28 , A61P27/02 , A61P43/00 , C07D209/08 , C07D211/10 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/58 , C07D211/70 , C07D213/38 , C07D213/42 , C07D213/71 , C07D215/36 , C07D217/02 , C07D217/08 , C07D231/18 , C07D231/56 , C07D233/84 , C07D239/42 , C07D241/04 , C07D241/18 , C07D241/50 , C07D261/10 , C07D265/36 , C07D271/12 , C07D277/20 , C07D277/42 , C07D277/62 , C07D285/14 , C07D295/22 , C07D307/82 , C07D319/18 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/12 , C07D413/04 , C07D471/04 , C07D487/04 , C07D487/08 , C07D491/113 , C07D513/04
CPC classification number: C07D241/38 , C07D207/48 , C07D209/08 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/38 , C07D211/54 , C07D211/58 , C07D211/62 , C07D211/76 , C07D211/96 , C07D213/70 , C07D213/74 , C07D215/04 , C07D215/42 , C07D215/58 , C07D217/02 , C07D217/06 , C07D217/08 , C07D217/22 , C07D217/24 , C07D231/18 , C07D231/56 , C07D233/42 , C07D235/26 , C07D239/14 , C07D241/08 , C07D241/50 , C07D261/10 , C07D265/36 , C07D271/12 , C07D277/56 , C07D277/58 , C07D277/62 , C07D279/16 , C07D285/14 , C07D285/16 , C07D295/26 , C07D307/68 , C07D307/79 , C07D333/62 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/12 , C07D413/04 , C07D471/08 , C07D487/04 , C07D487/08 , C07D491/10 , C07D513/04
Abstract: PROBLEM TO BE SOLVED: To provide novel hydroxysteroid dehydrogenase inhibiting compounds.SOLUTION: There are provided the following compounds, and further pharmaceutical compositions containing the same for type-2 diabetes, osteoporosis, hypertension, ocular disorders, cognitive disorders, the metabolic syndrome and other metabolic disorders.
Abstract translation: 待解决的问题:提供新的羟类固醇脱氢酶抑制化合物。 提供以下化合物,以及其它含有2型糖尿病,骨质疏松症,高血压,眼部疾病,认知障碍,代谢综合征和其他代谢紊乱的药物组合物。 版权所有(C)2013,JPO&INPIT